---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: RIZE"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: RIZE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 59 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence/rize"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: RIZE

<a id="heading-3.1.4"></a>

## 3.1.4 RIZE

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Objective in the trial registry

> “The objective of this trial is to evaluate the safety, tolerability and glucose-raising effects of RZ358 in patients with Congenital Hyperinsulinism (HI).”

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.1-2"></a>

#### Objectives in the primary publication

> “The objectives of this study were to evaluate the safety, tolerability, PK, PD, and glycemic efficacy of repeat bi-weekly doses of ersodetug over 8 weeks in participants with cHI.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Study dates in the trial registry

| Milestone | Quoted date |
| --- | --- |
| Study start (actual) | “2020-02-24” |
| Primary completion (actual) | “2022-04-05” |
| Study completion (actual) | “2022-08-19” |

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.2-2"></a>

#### Number of centers and countries

> “A total of 16 centers across 11 countries participated in the study.”
> “RIZE was conducted across 11 countries and three continents in order to capture the broadest potential study population to reflect the known heterogeneity of cHI.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.2-3"></a>

#### Study sites listed in the trial registry

| Country | Quoted site |
| --- | --- |
| United States | “The Children's Hospital of Philadelphia” |
| United States | “Cook Children's Medical Center” |
| Canada | “Research Institute of the McGill University Health Centre” |
| Denmark | “Odense University Hospital” |
| Germany | “Magdeburg University Clinic Center (Otto-von-Guericke Universität)” |
| Israel | “Edmond & Lilly Safra's Children Hospital” |
| Israel | “Hadassah Har Hazofim MC - Division of Pediatric Endocrinology” |
| Russia | “Endocrinology research center” |
| Spain | “Hospital Universitari Vall d' Hebron” |
| Turkey | “Adana Cukurova University Balcalı Hospital” |
| Turkey | “Hacettepe University” |
| Turkey | “Erzurum City Hospital” |
| United Kingdom | “Great Ormond Street Hospital” |

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.2-4"></a>

#### Topline results announcement

> “today announced positive data from its Phase 2b RIZE study of RZ358.”

Source: [Rezolute RIZE topline release (2022)](https://ir.rezolutebio.com/news/detail/296/rezolute-announces-positive-results-from-the-phase-2b-rize-study-of-rz358-in-congenital-hyperinsulinism)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Open-label, repeat-dose study in four sequential ascending-dose cohorts

> “The RIZE trial was a Phase 2, global, multi-center, open-label, repeat-dose study of ersodetug, conducted in four sequential ascending-dose cohorts in 23 participants with cHI ≥2 years-old with inadequately controlled hypoglycemia on standard-of-care (SOC) therapies.”
> “The study duration was approximately 28 weeks including a Screening Period of up to 35 days, Treatment Period of 8 weeks, and Follow-up Period of ∼3 months.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.3-2"></a>

#### Design description in the trial registry

> “This is a Phase 2, multicenter, open label clinical study designed to assess the safety and efficacy of four progressively higher doses of RZ358 in separate groups of patients with hyperinsulinemic hypoglycemia due to Congenital HI, not adequately controlled with or without current standard of care.”

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.3-3"></a>

#### Dose escalation oversight

> “The study was approved by country and local regulatory authorities and ethics committees and was supervised by a Dose Escalation Review Committee (DERC) which included three principal investigators.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.3-4"></a>

#### Add-on to standard of care with unchanged diet and activity

> “Participants continued with their respective SOC and maintained their usual diet and activity levels during the entire study from screening through follow-up.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.3-5"></a>

#### Protocol number and registrations

> “This study was sponsored by Rezolute, Inc. (clinical trial number RZ358-606) and registered at ClinicalTrials.gov (ClinicalTrials.gov: NCT04538989) and EudraCT (2016-004186-83).”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.3-6"></a>

#### Company description of the design

> “RIZE is a Phase 2b, multicenter, open label, repeat-dose study, designed to assess the safety and tolerability, pharmacokinetics, and glycemic efficacy of RZ358 administered bi-monthly for 8 weeks in patients with congenital hyperinsulinism whose hypoglycemia was not adequately controlled on standard of care therapies.”

Source: [Rezolute RIZE topline release (2022)](https://ir.rezolutebio.com/news/detail/296/rezolute-announces-positive-results-from-the-phase-2b-rize-study-of-rz358-in-congenital-hyperinsulinism)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Congenital hyperinsulinism with persistent hypoglycemia despite standard of care

> “Participants between the ages of 2–45 years old with biochemically proven cHI, irrespective of genetic etiology, were eligible for the study if they were experiencing persistent hypoglycemia despite being managed with currently available SOC therapy.”
> “Persistent hypoglycemia was defined as having three or more hypoglycemia events (<70 mg/dL; 3.9 mmol/L) per week by self-monitored blood glucose (SMBG) performed by point of care (POC) glucometer as well as glucose values < 70 mg/dL (3.9 mmol/L) for ≥4% of overall monitored time in a minimum 10-day CGM sensing period, including at least three severe hypoglycemia events (<50 mg/dL; 2.8 mmol/L) by CGM during the last 7 days of the sensing period.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.4-2"></a>

#### Exclusion criteria in the primary publication

> “Exclusion criteria included: those with clinically significant comorbidities, recent history of surgery, clinically significant out-of-range laboratory values (as determined per investigator), recent use of systemic corticosteroids, or adolescents and adults with a body mass index (BMI) in the Class 2 (BMI = 35.0–39.9) or greater obesity range.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.4-3"></a>

#### Inclusion and exclusion criteria in the trial registry, including exclusion of malignancy

> “Male or female age 2-45 years old (except age 12-45 in US) with an established clinical diagnosis of congenital hyperinsulinism”
> “Confirmed hypoglycemia as assessed by CGM, SMBG, and clinical evaluation, during Screening”
> “History of malignancy”
> “Use of systemic corticosteroids within 30 days before Screening”
> “Known or suspected allergy to the study drug”

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Dose regimens by cohort in the trial registry

| Cohort | Quoted intervention |
| --- | --- |
| Cohort 1 | “IV infusion for 8 weeks (3 mg/kg bi-weekly for 8 weeks)” |
| Cohort 2 | “IV infusion for 8 weeks (6 mg/kg bi-weekly for 8 weeks)” |
| Cohort 3 | “IV infusion for 8 weeks (9 mg/kg bi-weekly for 8 weeks)” |
| Cohort 4 | “IV infusion for 8 weeks (bi-weekly fixed dose-titration from 3 to 9 mg/kg for the first 4 weeks, followed by a fixed 9 mg/kg dose amount thereafter for the remaining 4 weeks)” |

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.5-2"></a>

#### Intravenous infusion over at least 30 minutes every other week, added to standard of care

> “Cohort 1 received 3 mg/kg, Cohort 2 received 6 mg/kg, Cohort 3 received 9 mg/kg, and Cohort 4 was a fixed dose titration cohort starting at 3 mg/kg and ending at 9 mg/kg.”
> “Within their respective dose cohorts, each participant received ersodetug by intravenous (IV) infusion over at least 30 min every other week (bi-weekly) for a total of eight weeks, added to their stable SOC management.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.5-3"></a>

#### Inpatient administration and follow-up visits

> “Enrolled participants were admitted to an inpatient unit at the study center the day prior to the first dose and at each subsequent bi-weekly administration of the study drug.”
> “Following each dose, participants were monitored under inpatient observation for at least 24 h.”
> “During the ∼3-month safety follow-up period, participants completed four outpatient visits at Days 14 (End of Treatment [EOT]), 28, 42, and 105 (final End of Study [EOS] visit) following the final dose of study drug.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.5-4"></a>

#### Rescue therapy

> “Rescue therapy guidelines based on hypoglycemia and hyperglycemia thresholds were provided to standardize the use of rescue therapy across the study, and to optimize the safety of study participants.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Percent Time in Glucose Target Range 70-180 mg/dL by Continuous Glucose Monitoring as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Registered primary outcome measures

> “Median of Average Daily Percent Time Within a Glucose Target Range of 70-180 mg/dL (3.9-10 mmol/L) by CGM at Baseline (BL) and End of Treatment (EOT)”
> “Median Percent Change of Average Daily Percent Time Within a Glucose Target Range of 70-180 mg/dL (3.9-10 mmol/L) by CGM From Baseline (BL)”
> “Repeat Dose Pharmacokinetics of RZ358”

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.6.1-2"></a>

##### Primary and key secondary glycemic endpoints in the primary publication

> “The key, clinically-relevant glycemic endpoints that were assessed included: change from baseline in the average daily percent-time within a glucose target range of 70–180 mg/dL (3.9–10 mmol/L) by CGM (primary endpoint), and the key secondary endpoints of change from baseline in the average weekly incidence of hypoglycemia events (<70 mg/dL [<3.9 mmol/L] and <50 mg/dL [2.8 mmol/L]) by SMBG, and change from baseline in the average daily percent-time with hypoglycemia (<70 mg/dL[<3.9 mmol/L] and <50 mg/dL [2.8 mmol/L] by CGM.”
> “Secondary and additional CGM-based glycemic endpoints such as measures of overnight hypoglycemia were also evaluated.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.6.1-3"></a>

##### Authors' assessment of time in range as an endpoint in congenital hyperinsulinism

> “Clinical target ranges for CGM have been developed specifically for the diabetes mellitus population, and treatment recommendations in this hyperglycemia-focused setting allow for a greater extent of time above range (>180 mg/dL) than was seen in nearly all ersodetug-treated cHI participants in the RIZE study.”
> “For cHI, a condition of over-insulinization where avoidance of hypoglycemia is the primary management goal, diabetes management guidelines and hyperglycemia avoidance are generally considered far less relevant, and TIR has less utility as a study endpoint for evaluating the efficacy and safety of investigational therapies in cHI.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.6.1-4"></a>

##### Hypoglycemia events and time in hypoglycemia as the clinically relevant outcomes

> “Key hypoglycemia outcomes with clinical relevance to the cHI patient population, namely change in weekly hypoglycemia event rate by SMBG and daily percentage of time in hypoglycemia by CGM, are presented in Table 4.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.6.1-5"></a>

##### Registered secondary outcome measures, including a fasting challenge

> “Median Percent Change of Average Weekly Overall, Moderate, and Severe Hypoglycemia Events by SMBG From Baseline (BL)”
> “Median Percent Change of Average Daily Percent Time With Overall, Moderate, and Severe Hypoglycemia by CGM From Baseline (BL)”
> “The occurrence of hypoglycemia during a 12 Hour fasting challenge.”
> “Median Percent Change of Average 8-hour Overnight Percent Time in Glucose Target Range of 70-180mg/dL by CGM From Baseline (BL)”

Source: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="topic-3.1.4.6.1-6"></a>

##### Glucose measurement devices and safety assessments

> “CGM was performed using Dexcom G6 and output into the specified endpoint parameters based on derivations detailed in the study statistical analysis plan.”
> “The interpretation of the safety and tolerability of ersodetug was based on the assessment of adverse events (AEs), vital signs, ECGs, physical examination results, infusion-site observations, hepatic ultrasound results, anti-drug antibody levels, and clinical safety laboratory evaluations.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Planned enrollment per cohort

> “Up to eight participants were to be enrolled into each of the four cohorts, with a requirement for at least three participants to be younger than ten years old in order to progress to the next cohort.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.7.1-2"></a>

##### Sample size not powered for the glycemic endpoints

> “This study and the chosen sample size were not powered to the primary or key secondary pre-specified endpoints.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.7.1-3"></a>

##### Participants analyzed in each population

> “The entire enrolled population (n = 23) was included and analyzed in the intention-to-treat (ITT), safety, and PK populations.”
> “The per protocol (PP) population included 20 and 22 participants for the blood glucose monitor (BGM)- and CGM-based glycemic endpoints, respectively.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.7.1-4"></a>

##### Exclusions from the per-protocol glucometer analyses in the trial registry

> “For efficacy outcomes, the PP Population included 20 participants for BGM-based glycemic endpoints due to endpoint-specific exclusions. One participant in Cohort 1 and one in Cohort 4 were excluded from the PP population BGM-based analyses because they failed to meet pre-specified minimum testing frequency by glucometer. One participant in Cohort 3 was also excluded from the PP population BGM analyses for stopping background SOC therapy after starting RZ358 in the study”

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Safety, pharmacokinetic, and per-protocol populations

> “The PK population (n = 23) comprised all participants who received at least one dose of ersodetug and for whom the obtained concentrations were considered to be sufficient and interpretable.”
> “The per protocol population comprised participants who completed at least 4 weeks of study drug without major protocol deviations and was used for the primary descriptive summaries and comparative analyses of the glycemic efficacy and PD biomarker endpoints. A secondary summary and analyses used the Intent to Treat Population (n = 23).”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.7.2-2"></a>

##### Baseline and end-of-treatment evaluable periods

> “The baseline for glycemic endpoints was a minimum of 10 days and defined as the period of time encompassing all glucose measurements used to qualify the participant’s eligibility and continuing up to the first dose of study medication. The end of treatment (EOT) Evaluable Period for glycemic endpoints was defined as the 2-week period following the final dose of study drug, corresponding to the bi-weekly dosing interval.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.7.2-3"></a>

##### Statistical methods: Wilcoxon signed-rank test of change from baseline

> “Inferential statistical comparisons were performed as appropriate using Wilcoxon sign-rank test (SAS 9.3) to compare and analyze the median change and significance level (p-value) from baseline to the EOT evaluable period.”
> “A stage-dependent and iterative population-PK model (2-compartment with linear clearance) was used to characterize the PK parameters by age group, which were also summarized descriptively.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Screened, enrolled, and completed participants

> “A total of 35 participants were screened for the study, and 23 participants were eligible and enrolled, as per the study design depicted in Figure 1.”
> “Screen failures were most commonly due to failure to meet inclusion criteria, such as the defined threshold of persistent hypoglycemia (n = 8) or the presence of an exclusion criteria (n = 4).”
> “All enrolled participants completed the entire treatment period and all follow-up visits; notably, no enrolled participants discontinued the study for any reason.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.1-2"></a>

##### Protocol violations leading to per-protocol exclusion

> “This was due to significant protocol violations that met per-protocol exclusion, including stopping background standard-of-care (SOC) therapy and inadequate self-monitored blood glucose (SMBG) measurement frequency.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.1-3"></a>

##### Participant flow in the trial registry

| Milestone | Cohort 1, 3 mg/kg | Cohort 2, 6 mg/kg | Cohort 3, 9 mg/kg | Cohort 4, 3 to 9 mg/kg |
| --- | --- | --- | --- | --- |
| Started | “4” | “8” | “8” | “3” |
| Completed | “4” | “8” | “8” | “3” |
| Not completed | “0” | “0” | “0” | “0” |

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Demographics and baseline disease characteristics, intention-to-treat population

| Parameter | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 8) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled (n = 23) |
| --- | --- | --- | --- | --- | --- |
| Age in years, mean (range) | “5.8 (2–12)” | “9.3 (2–22)” | “5.8 (2–17)” | “4.0 (2–6)” | “6.7 (2–22)” |
| Male, n | “4” | “5” | “3” | “1” | “13 (57%)” |
| KATP channel mutation, n | “1” | “5” | “4” | “1” | “11 (48%)” |
| Unknown genetic etiology | “3” | “2” | “3” | “1” | “9 (39%)” |
| Congenital HI therapy, n (%) | “4” | “7” | “6” | “3” | “20 (87%)” |
| Diazoxide | “2” | “3” | “1” | “2” | “8 (35%)” |
| Somatostatin analog (long acting/short acting) | “2/0” | “2/2” | “3/3” | “1/0” | “8/5 (52%)” |
| Enteral or tube use | “0” | “2” | “3” | “0” | “5 (22%)” |
| Pancreatectomy | “0” | “0” | “3” | “1” | “4 (17%)” |
| History of seizure, n | “4” | “4” | “5” | “3” | “16 (70%)” |
| Hospitalization within the past year, n | “3” | “3” | “6” | “2” | “14 (61%)” |
| Percent time in range (70–180 mg/dL) by CGM, mean (range) | “82 (74–89)” | “74 (66–89)” | “71 (12–90)” | “68 (57–87)” | “74 (12–90)” |
| Percent time in hypoglycemia (<70 mg/dL) by CGM, mean (range) | “16 (11–22)” | “22 (11–32)” | “24 (6–88)” | “29 (11–42)” | “23 (6–88)” |
| Hypoglycemia events/week (<70 mg/dL) by SMBG, mean (range) | “8 (1–13)” | “16 (4–52)” | “15 (7–29)” | “8 (4–11)” | “13 (1–52)” |

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.2-2"></a>

##### Age distribution, background therapy, and history of hospitalization and seizures

> “The study population ranged between 2 and 22 years old and was primarily pediatric, with a mean age of 6.7 years. The majority of participants (19 of 23 [83%]) were <12 years old, including 16 (70%) who were between 2 and 6 years old.”
> “Most participants (20/23 [87%]) were taking one or more stable SOC treatments, such as somatostatin analogs (52%), diazoxide (35%), and/or continuous enteral nutrition (22%), while the remaining participants (3/23, 13%) were not taking commonly used chronic medical therapies due to previous non-responsiveness or intolerance.”
> “At study entry, 14 participants (61%) reported being hospitalized an average of 1.7 times (range 1–4) within the year prior to study enrollment due to cHI-related hypoglycemia or associated complications. Additionally, 16 participants (70%) had a known history of hypoglycemia-related seizures, and nearly half (n = 11 [48%]) experienced either seizures or an altered level of consciousness (ALOC) requiring third-party intervention in the year preceding enrollment.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.2-3"></a>

##### Sex, race, and country of enrollment in the trial registry results

| Characteristic | Quoted total (n = 23) |
| --- | --- |
| Female | “13” |
| Male | “10” |
| White | “20” |
| Enrolled in Turkey | “7” |
| Enrolled in Russia | “5” |
| Enrolled in Bulgaria | “3” |

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="topic-3.1.4.8.2-4"></a>

##### Company-reported baseline characteristics

> “The RIZE study enrolled a diverse group of congenital HI patients with an average age of 6.5 years, including 16 patients between the ages of 2 and 6 years old, and with substantial continued hypoglycemia despite being on currently available therapies.”

Source: [Rezolute RIZE PES data release (2022)](https://ir.rezolutebio.com/news/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-congenital-hyperinsulinism)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Primary endpoint: percent time in range 70-180 mg/dL by CGM, per-protocol population

| Measure | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 7) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled (n = 22) |
| --- | --- | --- | --- | --- | --- |
| Median daily percent time in range at baseline | “81.7” | “72.9” | “83.4” | “59.3” | “76.9” |
| Median daily percent time in range at week 8 | “84.8” | “78.5” | “82.9” | “70.8” | “79.1” |
| Median percent change from baseline | “6.19” | “0.31” | “5.52” | “9.07” | “4.59” |

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="topic-3.1.4.8.3-2"></a>

##### Primary endpoint: time in range not significantly changed

> “Due to modest median increases in CGM time in mild hyperglycemia, the significant improvements in hypoglycemia time and events did not translate to a similar magnitude of improvement in CGM time in range (TIR; 70–180 mg/dL). In pooled participants across all dose levels, TIR (70–180 mg/dL) increased by a non-statistically significant median of ∼5%.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-3"></a>

##### Key secondary endpoints: hypoglycemia events by SMBG and time in hypoglycemia by CGM, per-protocol population

| Metric | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 7) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled, median (range) |
| --- | --- | --- | --- | --- | --- |
| Hypoglycemia events (<70 mg/dL) by BGM, events/week, baseline | “10.1” | “12.5” | “13.0” | “9.3” | “11.5 (4.0–52.0)” |
| Hypoglycemia events (<70 mg/dL) by BGM, events/week, end of treatment | “9.9” | “6.6” | “1.9” | “7.6” | “5.0 (0–23.8)” |
| Hypoglycemia events (<70 mg/dL), % change from baseline (p value) | “−1.6 (NS)” | “−48 (0.016)” | “−84 (0.016)” | “−19.9 (NS)” | “−59 (<0.001)” |
| Severe hypoglycemia events (<50 mg/dL), % change from baseline (p value) | “−40 (NS)” | “−78 (NS)” | “−100 (0.016)” | “−27 (NS)” | “−78 (0.005)” |
| Time in hypoglycemia (<70 mg/dL) by CGM, %, baseline | “16.3” | “20.3” | “13.7” | “34.4” | “16.2 (6–88)” |
| Time in hypoglycemia (<70 mg/dL) by CGM, %, end of treatment | “12.3” | “6.7” | “5.4” | “20.4” | “8.5 (0.3–34)” |
| Time in hypoglycemia (<70 mg/dL), % change from baseline (p value) | “−31 (NS)” | “−65 (0.023)” | “−61 (0.016)” | “−47 (NS)” | “−54 (<0.001)” |
| Time in severe hypoglycemia (<50 mg/dL), % change from baseline (p value) | “−22 (NS)” | “−74 (NS)” | “−85 (NS)” | “−61 (NS)” | “−65 (NS)” |

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-4"></a>

##### Key secondary endpoints: summary of reductions in hypoglycemia

> “Hypoglycemia (<70 mg/dL) events (self-monitored blood glucose) and time (continuous glucose monitoring) improved from baseline by medians of 59% (p < 0.001) and 54% (p < 0.001), respectively, across pooled dose levels and by 48%–84% (events) and 61%–65% (time) at doses of 6 or 9 mg/kg (p < 0.05) with a nearly universal individual patient response rate.”
> “Cohort 4, who received a fixed titration regimen, experienced blended improvements in total and severe hypoglycemia events of 20% and 27%, respectively. Generally, the observed glycemic changes and p values in cohorts 1 and 4 reflected lower overall doses as well as smaller group sizes.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-5"></a>

##### Individual responder rates

> “Across all study participants, including the minimally efficacious low dose of 3 mg/kg, there was a consistently high individual patient response rate to ersodetug, as a large majority of participants (88%–100% at the mid- and high-dose levels) achieved corrections in overall hypoglycemia of at least 50% measured by either CGM or SMBG, as shown in Table S2. At the highest dose, all participants achieved at least 50% improvement in severe hypoglycemia (<50 mg/dL), with all but one participant improving by at least 75%.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-6"></a>

##### Overnight hypoglycemia and time above range, per-protocol population

| Endpoint | Cohort 1, 3 mg/kg | Cohort 2, 6 mg/kg | Cohort 3, 9 mg/kg | Cohort 4, 3 to 9 mg/kg | Pooled |
| --- | --- | --- | --- | --- | --- |
| Overnight (8 h) percent time <70 mg/dL by CGM, % change (p value) | “−15.8 (NS)” | “−54.8 (NS)” | “−55.0 (NS)” | “−61.9 (NS)” | “−52.2 (0.006)” |
| Overnight (8 h) event rate <70 mg/dL by CGM, % change (p value) | “−15.5 (NS)” | “−49.3 (NS)” | “−42.9 (NS)” | “−56.5 (NS)” | “−40.7 (0.04)” |
| Percent time above range (>180 mg/dL) by CGM, net change | “+0.53” | “+6.7” | “+9.4” | “+10.4” | “+6.03” |
| Average overnight glucose (mg/dL) by CGM, net change | “−2.5” | “+21.5” | “+19.3” | “+19.8” | “+17.8” |

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-7"></a>

##### Overnight hypoglycemia: congress analysis

> “In a dose-dependent manner, across all dose levels, baseline overnight hypoglycemia time (13.6% time [65 min]) improved by a median of 52% (P = 0.001).”
> “Average overnight glucose shifted slightly from baseline median of 99 mg/dL to 113 mg/dL (P <0.001) at EOT.”

Source: [Dastamani et al. (2024)](https://abstracts.eurospe.org/hrp/0098/hrp0098fc14.3)

<a id="topic-3.1.4.8.3-8"></a>

##### Fasting challenge in the trial registry

| Measure | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 7) | Cohort 4, 3 to 9 mg/kg (n = 3) | Pooled (n = 22) |
| --- | --- | --- | --- | --- | --- |
| Participants able to complete fast at baseline | “3” | “2” | “0” | “0” | “5” |
| Participants able to complete fast at end of treatment | “3” | “1” | “2” | “1” | “7” |

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="topic-3.1.4.8.3-9"></a>

##### Rescue interventions and background therapy

> “During the study’s treatment period, three participants met rescue criteria and received a total of four rescue interventions for hypoglycemia, as determined by the investigator. Of the participants that received rescue interventions, only one participant required i.v. glucose, at a time frame early in the treatment period. No participants required continuous i.v. glucose supplementation at baseline or on treatment.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-10"></a>

##### Pharmacokinetics and pharmacodynamics

> “As expected of an intravenous (i.v.) medication, the exposures were predictable and dose dependent; plasma concentrations increased approximately proportional to dose across the ersodetug dose range of 3–9 mg/kg (Figure 2). The half-life of ersodetug was approximately 2 weeks.”
> “It was observed that pediatric exposures trended lower than adult exposures, with decreasing pediatric age.”
> “Dose-dependent increases in fasting and/or post-prandial insulin were observed, with average maximal increases of up to ∼10-fold at the 9 mg/kg dose level. Insulin levels declined at the conclusion of the treatment period and returned to baseline levels at approximately 4–6 weeks after stopping the study drug.”
> “Fasting and/or post-prandial BHOB levels, which are characteristically suppressed in cHI, increased dose dependently from baseline by a median of ∼2- to 3-fold across all dose cohorts.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.3-11"></a>

##### Company-reported results for the pooled 6 and 9 mg/kg doses

> “Pooled 6 and 9 mg/kg dose levels representative of Phase 3 population and dosing”
> “Improvement in time in hypoglycemia and overall events of ~75% and up to ~90% at top doses”
> “Nearly universal patient response rate (>50% hypoglycemia correction) observed at mid and top doses”

Source: [Rezolute September corporate presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925085892/tm2524786d1_ex99-2.htm)

> “RZ358 led to a better than 50% reduction from baseline in overall (<70 mg/dL) and severe (<50 mg/dL) hypoglycemia events (by BGM) and time in hypoglycemia (by CGM) in the pooled group of patients across all doses (see Table 1). A larger magnitude of improvement of ~75% was seen at the anticipated therapeutic doses of 6 mg/kg and 9 mg/kg.”

Source: [Rezolute RIZE PES data release (2022)](https://ir.rezolutebio.com/news/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-congenital-hyperinsulinism)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Overall safety: no deaths, adverse drug reactions, or discontinuations

> “There were no deaths, adverse drug reactions, discontinuations due to adverse events, treatment-emergent clinically significant organ system findings (e.g., laboratory abnormalities), or dose-limiting toxicities, as reviewed by the dose escalation review committee (DERC).”
> “No treatment-emergent clinically significant abnormalities were found in laboratory evaluations, including hepatic function parameters, or hepatic ultrasound examinations, physical examinations, or electrocardiograms (ECGs).”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-2"></a>

##### Overview of treatment-emergent adverse events, safety population

| Category | Pre-treatment non-TEAE, total (n = 23) | Cohort 1, 3 mg/kg (n = 4) | Cohort 2, 6 mg/kg (n = 8) | Cohort 3, 9 mg/kg (n = 8) | Cohort 4, titrate (n = 3) | Ersodetug, total (n = 23) |
| --- | --- | --- | --- | --- | --- | --- |
| Participants with adverse events, n (%) | “10 (43)” | “2 (50)” | “7 (88)” | “5 (63)” | “2 (67)” | “16 (70)” |
| Participants with serious adverse events, n (%) | “0 (0)” | “0 (0)” | “2 (25)” | “1 (13)” | “0 (0)” | “3 (13)” |
| Participants with investigator-judged study drug-related adverse events, n (%) | “2 (9)” | “0 (0)” | “2 (25)” | “1 (13)” | “0 (0)” | “3 (13)” |
| Participants with grade 3 (severe) adverse events, n (%) | “1 (4)” | “0 (0)” | “2 (25)” | “0 (0)” | “0 (0)” | “2 (9)” |
| Participants with grade 4 (life threatening) adverse events, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “1 (13)” | “0 (0)” | “1 (4)” |

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-3"></a>

##### Most common treatment-emergent adverse events

> “The most commonly reported TEAEs overall (reported by 2 or more of the ersodetug-treated study participants) were upper respiratory tract infection (n = 4, 17%), COVID-19 infection (n = 3, 13%), and anemia (n = 2, 9%). On a time-adjusted basis, there was no meaningful difference in the number of AEs during the study drug treatment period (41 TEAEs in 16 participants) compared to the pre-treatment period (17 non-TEAEs in 10 participants).”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-4"></a>

##### Serious adverse events

> “A total of three serious AEs occurred in 3 separate participants (hypoglycemia with loss of consciousness, seizure, and white blood cell increase) and were deemed by investigator(s) as related to background disease conditions and unrelated to the study drug and, thus, were not serious adverse reactions.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

| Serious adverse event | Cohort 1, 3 mg/kg | Cohort 2, 6 mg/kg | Cohort 3, 9 mg/kg | Cohort 4, 3 to 9 mg/kg |
| --- | --- | --- | --- | --- |
| “Hypoglycemia with LOC” | “0” | “1” | “0” | “0” |
| “Tonic-Clonic Seizure” | “0” | “0” | “1” | “0” |
| “Eosinophilic Leukocytosis” | “0” | “1” | “0” | “0” |

Source: [ClinicalTrials.gov NCT04538989 results](https://clinicaltrials.gov/study/NCT04538989?tab=results)

<a id="topic-3.1.4.8.5-5"></a>

##### Adverse events judged related to study drug, including infusion site reactions

> “Three participants experienced four non-serious and clinically mild TEAEs judged by investigator(s) to be related to the study treatment, including a 6 mg/kg participant with transient dizziness that followed the first administration of study drug, a 6 mg/kg participant with localized and transient infusion site reactions with the first 2 administrations of the study drug, and a 9 mg/kg participant with hyperactivity, which the investigator attributed to an improvement in hypoglycemia.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-6"></a>

##### Hyperglycemia

> “A modest, transient, and self-limiting increase in time in hyperglycemia (>180 mg/dL) by CGM from ∼2% at baseline to ∼8% after receiving ersodetug was observed in this study, in which participants were instructed to continue their background therapies. There was no increase in clinically relevant hyperglycemia events, and minimal increases in mild hyperglycemia were not dose dependent. Furthermore, there was no evidence of ketosis, no participant met criteria for and/or required insulin use, and no hyperglycemia-related AEs occurred.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-7"></a>

##### Immunogenicity

> “One of the 23 enrolled participants had minimally detectable anti-drug antibodies (ADAs), with a low titer of <1:40 and no evidence of immune reaction or neutralizing antibodies against ersodetug.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="topic-3.1.4.8.5-8"></a>

##### Company-reported exposure margin to nonclinical toxicology studies

> “The observed blood levels of RZ358 were well below levels that were safely tested in long term toxicology studies in non-human primates.”

Source: [Rezolute RIZE PES data release (2022)](https://ir.rezolutebio.com/news/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-congenital-hyperinsulinism)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

- Design: RIZE was an open-label, uncontrolled study of 23 participants with sequential dose cohorts and 8 weeks of treatment, and its sample size was not powered for the primary or key secondary endpoints.
- Population: participants had congenital hyperinsulinism and were 2 years of age or older, so the study provides indirect evidence of efficacy for adults with tumor hyperinsulinism.
- Outcome: the improvements in hypoglycemia did not translate into a similar improvement in time in range, the registry primary endpoint. The registry reports this endpoint as medians in the per protocol population, while the publication reports means in the intention-to-treat population.
- Reporting: the registry results and the publication differ on sex distribution, and the 2022 company releases describe dosing as “bi-monthly” where the publication gives “every other week (bi-weekly)”.

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8); [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989); [Rezolute RIZE topline release (2022)](https://ir.rezolutebio.com/news/detail/296/rezolute-announces-positive-results-from-the-phase-2b-rize-study-of-rz358-in-congenital-hyperinsulinism); [Rezolute RIZE PES data release (2022)](https://ir.rezolutebio.com/news/detail/299/rezolute-announces-positive-data-from-its-phase-2b-rize-study-of-rz358-in-patients-with-congenital-hyperinsulinism)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
